ObjectiveTo compare and analyze the clinical effects of crizotinib or gefitinib combined with GP regimen (gemcitabine + cisplatin) in the treatment of patients with advanced non-small cell lung cancer and its effect on patients′ immune function and life quality. MethodsA total of 150 non-small cell lung cancer patients admitted to our hospital from January 2018 to February 2021 were selected as the research objects, and they were divided into observation group and control group according to the random number method, with 75 cases in each group. Patients in the observation group were treated with gefitinib based on GP regimen, while patients in the control group were treated with the GP regimen in combination with crizotinib. After 30 days of treatment, the clinical efficacy of the two groups was compared. The changes of T lymphocyte subsets were compared between the two groups before and after treatment. The scores of the mos 36-item short form health survey (SF-36) and karnofsky performance status (KPS) before and after treatment were compared between the two groups. The occurrence of adverse reactions between the two groups during treatment was compared. ResultsWith 30 days of treatment, there were no statistically significant differences in total effective rate of treatment and control rate between the two groups (P＞0.05). After 30 days of treatment, the levels of CD3+ and CD4+ T lymphocytes and the ratio of CD4+ / CD8+ increased significantly, while the levels of CD8+ T lymphocytes decreased significantly in both groups, with statistically significant differences (P＜0.05). However, there were no significant differences in the levels of CD3+, CD4+ and CD8+ T lymphocytes and the ratio of CD4+ / CD8+ between the two groups before and after treatment (P＞0.05). After 30 days of treatment, the SF-36 and KPS scores of the two groups increased significantly (P＜0.05); however, there were no statistically significant differences in SF-36 and KPS scores between two groups before and after treatment (P＞0.05). During treatment, there was no statistically significant difference in the occurrence of adverse reactions between two groups (P＞0.05). ConclusionGefitinib or crizotinib combined with GP regimen are both safe and effective in the treatment of patients with advanced non-small cell lung cancer, which can effectively control disease progression, regulate the immune function of patients, and improve the life quality of patients. Clinically, appropriate targeted therapy drugs should be selected for clinical therapy according to the specific situation of patients.

无